Navigation Links
Catheter Ablation Effective in Treating Atrial Fibrillation
Date:5/14/2009

Burning faulty tissue better than meds for irregular heartbeat, study suggests

THURSDAY, May 14 (HealthDay News) -- Treating an irregular heartbeat by searing faulty heart tissue may be more effective than treating with medication, a new study shows.

Nearly two-thirds of study participants with atrial fibrillation experienced no such condition-related symptoms one year after having a catheter ablation, a procedure in which heart tissue responsible for the erratic electrical signals throwing off the organ's pumping rhythm is burned and destroyed. Only 17 percent of those in the study treated for the condition with medications reported being arrhythmia-free in the same period.

Those who had the surgical procedure also said they experienced a great improvement in their quality of life.

The international study's 167 participants, all of whom had previously been unable to control the condition with medication alone, had been randomly assigned to either have the heart procedure or be treated for it with medications, according to the research, lead by Dr. David Wilber, director of the Cardiovascular Institute at Loyola University Stritch School of Medicine, in Maywood, Ill.

Wilber was scheduled to present his team's findings Thursday at the Heart Rhythm Society's annual meeting in Boston. The study was funded by Biosense Webster, maker of the ThermoCool catheter used in the trial, and Wilber is a consultant to the company.

More than 2 million Americans have atrial fibrillation, making it the most common of heart rhythm disorders. The electrical signals to the heart become irregular, causing the organ's upper chambers to pump out of rhythm. The condition can cause heart palpitations, dizziness, fatigue, shortness of breath and fainting that lead to a person having a lack of energy, feeling of weakness and a poor quality of life. It can also lead to stroke and heart failure.

Doctors often first prescribe beta blockers, calcium channel blockers, flecainide or propafenone to try to improve the condition before resorting to surgical options such as installing a pacemaker or catheter ablation.

In catheter ablation, doctors guide a thin flexible tube through blood vessels to the heart. Radiofrequency energy directed from the tube's tip heats and destroys the tissue causing the bad electrical signals. The procedure's risks include creating fluid in the lungs or around the heart, bleeding, clots and stroke.

Another study, involving about 3,000 atrial fibrillation patients who will be followed for three years, will try to determine whether those who have catheter ablation live longer those using medication for the condition, according to background information in a Loyola University news release on the study.

More information

The American Heart Association has more about atrial fibrillation.



-- Kevin McKeever



SOURCE: Loyola University Health System, news release, May 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
2. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
3. Catheter angiography may be an unnecessary follow-up to CT angiography
4. Massive necrosis after trans-catheter treatment is more common in the presence of tumor capsule
5. Catheter chaos: Hospitals lag in preventing common infection
6. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
7. Balloon catheter-based sinus surgery radiation exposure very low, safe
8. St. Davids Medical Center First in Texas to Implement Visually Guided Catheter Ablation for Atrial Fibrillation
9. Led by Cardiovascular Applications, Double Digit Growth Expected for Catheter Sales
10. Catheter repair of mitral valve improves heart size, symptoms
11. Verathon(R) Offers Enhanced BladderScan(R) Instrument as Part of Continued Program to Eliminate Unnecessary Catheterizations, Decrease Urinary Tract Infections and Assist in Hospital Infection Control
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Catheter Ablation Effective in Treating Atrial Fibrillation
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: